Auro Labs. — 360° view

Auro Labs, a company in the Pharmaceuticals industry, reported revenue of ₹14 crore and net profit of ₹1.17 crore for the September 2026 quarter.

Auro Labs. (BSE: AUROLAB) closed at ₹248.75 on 20 Nov 2026, down 3.6% over the past year. Its market capitalisation is ₹155 crore and it trades at 29.6 times earnings.

Share price
₹248.75 (20 Nov 2026)
Market cap
₹155 Cr (20 Nov 2026)
P/E
29.59 (20 Nov 2026)
Revenue
₹14 Cr (September 2026 quarter)
Net profit
₹1 Cr (September 2026 quarter)
ROCE
9.52% (FY26)
ROE
8.49% (FY26)
Book value
₹77.9 (FY26)
Dividend yield
0.00% (FY26)
52-week high / low
₹317.00 / ₹199.95 (20 Nov 2026)
1-year return
-3.6% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
BSE: AUROLAB

Incorporated in 1989, Auro Laboratories Ltd is in the business of Bulk Drugs

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.